The prevalence of diseases and conditions such as Cardiovascular Diseases (CVDs), asthma, cancer, neurological disorders, stroke, diabetes, and respiratory diseases has increased significantly over some time. Mentioned below are some of the important statistics related to some of the chronic diseases. The rising prevalence of chronic and non-chronic diseases significantly influences the growth of the drug delivery devices market. Chronic diseases such as diabetes, cardiovascular diseases, and respiratory disorders are becoming more widespread, necessitating long-term treatment plans that require efficient and reliable drug delivery device methods.
Access Full Report @ https://www.databridgemarketresearch.com/ru/reports/global-drug-delivery-devices-market
Data Bridge Market Research analyzes that the Global Drug Delivery Devices Market is growing with a CAGR of 8.0% in the forecast period of 2024 to 2031 and is expected to reach USD 3,164.51 billion by 2031 from USD 1,748.63 billion in 2023.
Key Findings of the Study
Growth in the Development of Biologics Drugs Devices
Biologics is considered one of the fastest-growing segments in the pharmaceutical market. Development and manufacturing of biologics for both branded and generic drugs is becoming increasingly competitive with the presence of players. Biologics are generally administered through injections in the arms, legs or abdomen. For instance, Cimzia, Cosentyx, Enbrel, and Humira among others.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2024 to 2031
|
|
Base Year
|
2023
|
|
Historic Year
|
2022 (Customizable 2016-2021)
|
|
Quantitative Units
|
Revenue in USD Billion
|
|
Segments Covered
|
Product Type (Oral Drug Delivery, Injectable Drug Delivery, Topical Drug Delivery, Ophthalmic Drug Delivery, Nasal Drug Delivery, Pulmonary Drug Delivery, Transmucosal Drug Delivery, and Implantable Drug Delivery), End User (Hospitals, Home Healthcare, Clinics, Community Healthcare and Others), Distribution Channel (Direct Tenders, Hospital Pharmacies, Pharmacy Stores, and Online Pharmacy)
|
|
Countries Covered
|
U.S., Canada, Mexico, Germany, U.K., Italy, France, Spain, Russia, Switzerland, Turkey, Belgium, Netherlands, rest of Europe, Japan, China, South Korea, India, Singapore, Thailand, Indonesia, Malaysia, Philippines, Australia, rest of Asia-Pacific, Brazil, Argentina, rest of South America, South Africa, Egypt, Saudi Arabia, U.A.E., Israel, and rest of Middle East and Africa
|
|
Market Players Covered
|
BD (Singapore), F. Hoffmann-La Roche Ltd (Switzerland), Novartis AG (Switzerland), Sanofi (France), Johnson & Johnson Services, Inc. (U.S.), Bayer AG (Germany), 3M (U.S.), Gerresheimer AG (Germany), Medmix (Switzerland), OraSure Technologies Inc. (U.S.), Enable Injection (U.S.), Insulet Corporation (U.S.), Pfizer Inc. (U.S.), GSK plc. (U.K.), Merck & Co., Inc. (U.S.), Amgen Inc. (U.S.), AbbVie Inc. (U.S.), Elcam Medical (Israel), SMC Ltd. (U.S.), ViVO Smart Medical Devices Ltd. (England), West and Pharmaceutical Services, Inc. (U.S.) among others
|
|
Data Points Covered in the Report
|
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework
|
Segment Analysis
Global drug delivery devices market is segmented into three notable segments which are based on product type, end user, and distribution channel.
- On the basis of product type, the global drug delivery devices market is segmented into oral drug delivery, injectable drug delivery, topical drug delivery, ophthalmic drug delivery, nasal drug delivery, pulmonary drug delivery, transmucosal drug delivery, and implantable drug delivery
In 2024, the oral drug delivery segment is expected to dominate the global drug delivery devices market
In 2024, the oral drug delivery segment is expected to dominate the market with a market share of 40.57% due to its convenience, patient preference, and cost-effectiveness, making it the most widely used and accessible method of administering medications.
- On the basis of end user, the global drug delivery devices market is segmented into hospitals, home healthcare, clinics, community healthcare and others
In 2024, the hospitals segment is expected to dominate the global drug delivery devices market
In 2024, the hospitals segment is expected to dominate the market with a market share of 39.10% due to their extensive use of advanced devices for precise and controlled medication administration in critical care and inpatient settings.
- On the basis of distribution channel, the global drug delivery devices market is segmented into direct tenders, hospital pharmacies, pharmacy stores, online pharmacy. In 2024, the direct tenders segment is expected to dominate the market with a market share of 65.68%
Major Players
Data Bridge Market Research analyzes Johnson & Johnson Services, Inc. (U.S.), Novartis AG (Switzerland), F. Hoffmann-La Roche Ltd (Switzerland), Bayer AG (Germany), Pfizer Inc. (U.S.) as the major market players of the market.
Market Developments
- In May 2024, Enable Injections, and Serina Therapeutics have partnered to develop and commercialize SER-252 (POZ-apomorphine) with the enFuse platform for Parkinson’s disease treatment. This collaboration will enhance both companies' product portfolios and market reach by combining advanced drug delivery technology with innovative therapeutics
- In May 2024, Enable Injections, has expanded its partnership with Roche to integrate its enFuse delivery technology into Roche’s development programs, granting Roche an exclusive global license for combining enFuse with its molecules. Enable will handle clinical and commercial manufacturing of the enFuse system. This partnership will boost Enable's market presence and revenue through expanded use of its technology in Roche’s programs
- In February 2024, AbbVie Inc. and Tentarix Biotherapeutics have announced a partnership to collaboratively discover and develop conditionally-active, multi-specific biologics in the fields of oncology and immunology. This collaboration will leverage AbbVie's extensive experience in these areas alongside Tentarix's proprietary Tentacles platform
- In August 2023, Janssen Pharmaceutical Companies of Johnson & Johnson Services, Inc. submitted the supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) seeking sanction of DARZALEX in combination with Kyprolis and dexamethasone for relapsed/refractory multiple myeloma. If approved this will increase the product portfolio and also revenue generation of the company
- In June 2023, Novartis was signed an agreement to divest ‘front of eye’ ophthalmology assets to Bausch + Lomb, a global eye health company, in a transaction valued up to USD 2.5 billion, including USD 1.75 billion in upfront cash, plus additional milestone payments. The deal includes Xiidra, the first approved prescription treatment for the signs and symptoms of dry eye disease, and investigational medicine SAF312 (libvatrep), in development as a first-in-class therapy for chronic ocular surface pain (COSP), as well as the rights for use of the AcuStream delivery device in dry eye indications and OJL332, a second generation TRPV1 antagonist in pre-clinical development
- In February 2023, F. Hoffmann-La Roche Ltd expanded collaboration with Janssen to advance personalised healthcare through companion diagnostics. This has helped the company to strengthen its product portfolio
- In June 2022, Novartis acquires Kedalion Therapeutics and its innovative ocular delivery platform that could transform patient experience, an innovative device that have the potential to facilitate precise dosing and accurate delivery of certain topical ophthalmic medications to the eye1,2. The acquisition enhances the Novartis ophthalmics portfolio, advancing efforts to investigate transformative ophthalmic methods to address unmet patient needs in front-of-eye conditions
Regional Analysis
Geographically, the countries covered in the global drug delivery devices market report are the U.S., Canada, Mexico, Germany, U.K., Italy, France, Spain, Russia, Switzerland, Turkey, Belgium, Netherlands, rest of Europe, Japan, China, South Korea, India, Singapore, Thailand, Indonesia, Malaysia, Philippines, Australia, rest of Asia-Pacific, Brazil, Argentina, rest of South America, South Africa, Egypt, Saudi Arabia, U.A.E., Israel, and rest of Middle East and Africa.
As per Data Bridge Market Research analysis:
North America is the dominant region in the global drug delivery devices market during the forecast period of 2024 to 2031
North America is expected to dominate the market due to its advanced healthcare infrastructure, high R&D investment, and strong presence of key pharmaceutical and medical device companies.
Asia-Pacific is estimated to be the fastest-growing region in the global drug delivery devices market during the forecast period of 2024 to 2031
Asia-Pacific is expected to grow during the forecast period due to increasing healthcare investments, rising demand for advanced drug delivery systems, and a growing population with unmet medical needs.
For more detailed information about the global drug delivery devices market report, click here – https://www.databridgemarketresearch.com/ru/reports/global-drug-delivery-devices-market
